|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Objectives | Relevant Paper | Methodology | Paper About |
| Objectives 1 | Develop an AI-driven virtual screening platform for identifying PPI inhibitors targeting CFTR-related interactions | **Trepte et al. (2024) –** *AI-guided pipeline for prioritizing and targeting protein–protein interactions* | PPI Mapping  Structure Prediction  Scoring System  Virtual  Screening | -Describes an integrated AI pipeline combining **machine learning**, **AlphaFold-Multimer**, and **VirtualFlow** for identifying and ranking PPI targets.  -Offers a scalable and modular framework adaptable to CFTR PPI discovery. |
| Objectives 2 | Validate shortlisted inhibitors through molecular docking, molecular dynamics simulations, and binding free energy calculations | **Tang et al., (2024) -** *In silico discovery of potential PPI*  *inhibitors for anti-lung cancer*  *activity by targeting the*  *CCND1-CDK4 complex via the*  *P21 inhibition mechanism* | Protein Preparation  Molecular Docking  Molecular Dynamics (MD) Simulation  Binding Free Energy Calculations | -Outlines a full validation workflow using **AutoDock**, **MD simulations**, and **MM/GBSA binding energy** calculations.  -Shows practical examples of ranking and validating PPI-targeting compounds. |
| Objectives 3 | Apply machine learning models for predicting and ranking small molecules based on binding affinity, interaction profiles, and therapeutic potential | **Trepte et al. (2024) –** *AI-guided pipeline for prioritizing and targeting protein–protein interactions* | Machine Learning Algorithm – SVM  Feature Engineering for Small Molecule Ranking  Ranking Strategy  Validation and Scoring | -A **support vector machine-based model (SVM)** was developed to classify high-confidence PPIs using data from multiple binary interaction assays.  -Compounds screened using **VirtualFlow**, with binding interfaces to target PPI  -Compounds were ranked based on combined features from ML classification scores and docking performance.  -Experimental results confirmed the **biological activity** of top-ranked compounds. |
| Objectives 4 | Evaluate ADMET and pharmacokinetic profiles of lead compounds using AI-based predictive tools | **Basu et al. (2024) –** *Cystic Fibrosis: AI in Prognosis and Drug Discovery* | AI-Driven Repurposing  ADMET Prediction  Integration - Drug-likeness and Bioavailability | -Highlights the application of **AI-based tools like pkCSM, SwissADME**, and ML models for **ADMET prediction** and drug-likeness evaluation.  -Applies specifically to CF-related candidate screening pipelines. |